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Abstract 
Microtubules and carbon nanotubes (CNTs), and more particularly multi-walled CNTs (MWCNTs), share many mechan-
ical and morphological similarities that prompt their association into biosynthetic tubulin filaments both, in vitro and 
in vivo. Unlike CNTs, microtubules are highly dynamic protein polymers that, upon interaction with these nanomateri-
als, display enhanced stability that has critical consequences at the cellular level. Among others, CNTs prompt ectopic 
(acentrosomal) microtubule nucleation and the disassembly of the centrosome, causing a dramatic cytoskeletal 
reorganization. These changes in the microtubule pattern trigger the generation of ineffective biomechanical forces 
that result in migration defects, and ultimately in spindle-assembly checkpoint (SAC) blockage and apoptosis. In this 
review, we describe the molecular mechanism involved in the intrinsic interference of CNTs with the microtubule 
dynamics and illustrate the consequences of this effect on cell biomechanics. We also discuss the potential applica-
tion of these synthetic microtubule-stabilizing agents as synergetic agents to boost the effect of classical chemo-
therapy that includes spindle poisons (i.e. paclitaxel) or DNA interfering agents (5-fluorouracil)-, and list some of the 
advantages of the use of MWCNTs as adjuvant agents in preventing cell resistance to chemotherapy.
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Carbon nanotubes
Carbon nanotubes (CNTs) are materials with excep-
tional properties from the physicochemical point of view 
that are becoming increasingly important in the field of 
nanobiotechnology. Their reactive surface allows these 
nanofilaments to capture large amounts of biomolecules 
on their corona [1–3]. This CNT proteinaceous coating 
behaves as biological camouflage that endows the nano-
tubes with the ability to selectively interact with recep-
tor proteins or participating in specific protein-protein 
interactions [2, 4, 5]. CNTs are also well-known to adsorb 
many different types of inorganic molecules or drugs 
[6–16] or nucleic acids [9, 17] all of the great interest in 
nanomedicine. Finally, at the elementary level, CNTs are 
pure carbon and this composition makes them highly 
biocompatible since carbon represents ca. 18% of the 
composition of the human body.
Another interesting feature of CNTs is their one-
dimensional morphology. This property—very attractive 
from a biotechnological point of view—endows nano-
tubes with the unique ability to penetrate inside cells 
and cross tissues. But, from a biotechnological level, this 
feature represents a double edge sword since, CNTs can 
penetrate through most biological barriers causing puta-
tive potential long-term effects. This fact, in addition to 
their bio-persistence, are some of the great obstacles that 
make the use of CNTs in nanomedicine a matter of much 
debate.
Most studies that investigate the biological conse-
quences of CNTs demonstrate very significant pheno-
typic effects. These nanofilaments have been reported to 
trigger the production of reactive oxygen species [18–22], 
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[27–30], anti-proliferative [31–33] and anti-migratory 
[18, 34–36] effects, etc. Unfortunately, some early toxic-
ity studies were carried out using aggregated or poorly 
purified CNTs -containing traces of contaminating met-
als-, or were produced using unrealistic amounts of the 
nanotubes. This all resulted in poorly reproducible and 
unpredictable deleterious biological behaviours, leav-
ing a blurry picture of CNTs toxicity that has not been 
resolved until recently.
We now know that individualized CNTs (non aggre-
gated) can interfere with many cellular processes, and 
to what extent the nature, surface properties, and size 
of the nanotubes are important in this process. One of 
the greatest cellular effects caused CNTs results from 
their interaction with intracellular filaments, principally 
with the DNA, actin, and, above all, with the microtu-
bule cytoskeleton. CNT interactions with these biologi-
cal polymers have been reported to trigger clastogenic 
effects (DNA breakage), mitotic aberrations, chromo-
some missegregation, and migratory defects, all leading 
to a general cellular malfunction that eventually leads to 
apoptosis.
  Interestingly, the cellular phenotype produced by dif-
ferent CNTs is not identical. For instance, single-walled 
CNTs (SWCNTs) have been mostly reported to cause 
DNA damage [18, 23, 27, 37], while MWCNTs, appear 
to preferentially interfere with actin [38–40] and tubu-
lin, hindering cellular biomechanics (Fig. 1) [31, 36, 41]. 
These cellular phenotypes suggest the thickness of the 
nanotubes could be a significant issue in their interac-
tion with intracellular filaments and, more particularly, 
with the interaction of the nanotubes with the dynamic 
polymeric cytoskeletal filaments, such as microtubules or 
actin microfilaments.
Microtubules
Microtubules are intracellular tubulin polymers that con-
stitute a major component of cytoskeletal networks in 
all eukaryotic cells. Microtubules are involved in critical 
vital functions including DNA segregation during cell 
division, intracellular vesicular trafficking, and organelle 
distribution, providing a general structural cellular sup-
port, and are pivotal elements in cell migration [42]. The 
microtubular cytoskeleton is characteristically organ-
ized as an intracellular radial network that nucleates in a 
structure known as the centrosome, close to the nucleus. 
During cell division, the microtubular network typically 
reorganizes, first depolymerizing completely, to imme-
diately repolymerize assembling a spindle-shaped struc-
ture, the so-called ‘mitotic spindle’, responsible for sister 
cell separation.
Microtubules get their name from their tubular struc-
ture [43, 44]. These are 25 nm diameter protein twisted 
cylinders constituted of 13 protofilaments assembled 
upon a head-to-tail alignment of αβ-tubulin heterodi-
mers (Fig.  1b). This fact confers microtubules with an 
intrinsic polarity that results in different properties at 
both ends of the microtubule [45, 46]. The end containing 
α-tubulin (Fig. 1b) is located in the centre of the cell in a 
structure known as the “centrosome” where microtubules 
nucleate. And the other end, displaying a β-tubulin mol-
ecule, is localized in the cell periphery. This microtubule 
extreme (the so-called `+´ end) is highly dynamic, and it 
is constantly undergoing cycles of polymerization-depo-
lymerization [46]. This remarkable behaviour, known as 
`dynamic instability´, increases up to 20 times during 
mitosis when the microtubule cytoskeleton has to assem-
ble the mitotic spindle [47].
In vivo, microtubule polymerization-depolymeriza-
tion cycles are tightly regulated by numerous cell fac-
tors, mostly microtubule-associated proteins [48] while 
in  vitro polymerization is mostly tubulin-concentration 
dependent [49]. As an average, tubulin has an intracellu-
lar concentration of ca. 5 µM, independently of the stage 
of the cell cycle. This is cell-dependent but, in general, 
represents a median of 4.5–5% of the total soluble cellu-
lar protein [50, 51].
The implications of the microtubule cytoskeleton in 
cell division make it a classical target of chemotherapy. 
Antitumoral drugs interfering with microtubule dynam-
ics, also known as spindle poisons, effectively block cell 
proliferation, activating the metaphase spindle-check 
point (SAC), finally unchaining a cell “suicide” effect 
leading to apoptotic cell death (see below) [47, 52, 53]. 
The effect of some of these drugs is reviewed in the next 
sections has the ultimate goal to interfere with the for-
mation of the mitotic spindle, blocking the separation of 
daughter (or sister) cells, finally triggering apoptosis [52]. 
These molecules, broadly used in the treatment of can-
cer, include a series of different compounds that typically 
target β-tubulin, interfering with the polymerization or 
depolymerization dynamics of the protofilament thus, 
behaving either as microtubule-destabilizing or microtu-
bule-stabilizing agents [41].
MWCNTs are similar to microtubules
  MWCNTs and microtubules share several aspects of 
their architecture and properties (Fig. 2). Indeed, MWC-
NTs have been proposed as the technological counter-
part of nature’s microtubules [54]. They both have similar 
dimensions, a tubular morphology constituted of subu-
nits that self-assemble that ensures structural efficiency. 
Both have analogous physical properties (for example, 
shear stress, bending stiffness, and Young´s modulus), a 
highly reactive surface, and both are exceptionally resil-
ient [55, 56]. The greatest difference between these two 
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filaments, which has critical implications in vivo, is their 
dynamic behaviour. While MWCNTs are stable fila-
ments, microtubules, as reviewed in the previous section, 
are highly dynamic protein polymers [46].
  Similarities between CNTs and microtubules prompt 
their association both, in  vitro [54, 57] and in  vivo [31, 
41] into mixed hybrid tubulin polymers (Fig. 3). In vitro 
upon incubation, tubulin polymerizes on CNTs assem-
bling mixed polymers that allow microtubule motor 
(dynein–kinesin) “walking” on them, generating func-
tional microtubule-like structures [58, 59]. Intracellu-
larly, CNTs, and more particularly MWCNTs, associate 
with the cytoplasmic tubulin. Similar to in vitro, tubulin 
in vivo uses the nanotube surface as a scaffold to polym-
erize assembling hybrid tubulin nanofilaments [31]. This 
association, demonstrated by different techniques, is 
patently observable during microtubule assembly in cold 
depolymerization-re-polymerization experiments. Upon 
Fig. 1 Similarities between intracellular filaments and CNTs. a Tubulin protofilaments,actin microfilaments, and DNA have all been reported 
to interact with CNT. SWCNTs are very similar in size to DNA. This could explain their intrinsicclastogenic (DNA-breaking) effect. b MWCNTs 
display diameters thatvary between 4 and 25 nm. MWCNTs and microtubules share many morphologicalfeatures. Ultrastructurally, MWCNTs and 
microtubules are very similar.Microtubule SEM image is adapted from Burgess et al. Nat. Comm. (2015)6:8179
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temperature permissive conditions are applied, tubulin 
protofilaments polymerized ectopically throughout the 
cytoplasm, while in untreated cells, microtubules typi-
cally nucleate at the centrosome (Fig. 4). The hypothesis 
is that tubulin polymerization on the nanotube changes 
the protofilament curvature, stabilizing the now aligned 
tubulin heterodimers. As a consequence, these hybrid 
microtubules lose their ability to depolymerize abruptly. 
The resulting intracellular hybrid disorganized microtu-
bules are quasi-functional but display enhanced stability 
[31, 32, 41, 57].
  This makes the microtubule nucleation independent 
of the centrosome, increasing microtubule ectopic nucle-
ation throughout the cytoplasm (tubulin polymerization 
is no longer radial) resulting in an acentrosomal disposi-
tion of the hybrid microtubules in the cells (Fig. 5). Thus, 
cells treated with CNTs, display changes in the microtu-
bule pattern where the radial microtubule organization is 
substituted by a parallel microtubule array that runs from 
side to side of the cytoplasm, similar to that in yeast or 
plant cells (Fig. 5). This change in the arrangement of the 
microtubule network causes an alteration in the patterns 
of intracellular forces. Given the importance of the cen-
trosome as the director of the cell migratory phenomena, 
its disassembly generates important deleterious biome-
chanical effects upon force generation, that result in a 
loss of directionality during migration, a slower and more 
disordered migration all producing a significant reduc-
tion in the cellular migration speed (Fig. 6) [34–36].
  In proliferating cells, MWCNTs typically interfere 
with spindle formation. Aberrant spindles (i.e. acen-
trosomal or multipolar) are common in metaphase, 
triggering proapoptotic effects that result in the SAC 
activation apoptotic downstream effects. In resistant 
cells (i.e. cancer cells that have inhibited the apoptotic 
cascade) aberrant mitosis displaying aneuploidy and 
clastogenic effects, are common upon CNT treatment 
(Fig. 7).
Finally, some curiosities regarding the effect of CNTs 
in cellular biomechanics. MWCNTs also interfere with 
actin during cell division effects, typically resulting in 
multinucleated cells [34]. In macrophages, CNTs trigger 
cellular binucleation indicating that nanotubes interfere 
with the actomyosin contractile ring during cytokinesis, 
at the end of mitosis. Besides, macrophages treated with 
CNTs display a reduced phagocytic activity, thus sup-
porting the idea that MWCNTs interfere with the actin 
cytoskeleton [34, 39]. It is also very interesting that neu-
rons in the same cultures did not display observable dele-
terious changes upon exposure to CNTs, thus suggesting 
that cells that do not undergo intensive cytoskeletal rear-
rangements (such as the case of differentiated neurons) 
are not that much affected by nanotubes. Finally, all these 
remarkable effects disappear when identical doses of 
MWCNTs are not administered dispersed, i.e. attached 
to particles (500 nm diameter). No biomechanical imped-
ance, microtubule cytoskeletal reorganization, cytotoxic-
ity, or apoptosis is observed [60, 61], results that reinforce 
the hypothesis that to interact with tubulin, CNTs must 
be dispersed.
MWCNTs boost the effect 
of microtubule‑interfering drugs for cancer 
treatment and prevent resistance
  Cell proliferation is inherent in cancer and microtubules 
are key elements in this process thus, tubulin is a tradi-
tional target of many antitumor therapies. Microtubule-
stabilizing interfering agents-namely taxanes (paclitaxel, 
docetaxel, and cabazitaxel)-have become some of the 
most widely used and effective anticancer agents dur-
ing the last 50 years with efficacy towards a broad range 
of cancers. These drugs behave as microtubule poisons, 
interfering with microtubule dynamics, inhibiting the 
disassembly of the tubulin polymer. To do this, these mol-
ecules bind to a lateral structural pocket localized in the 
polymerized β-tubulin molecule (Fig. 8). Drug interaction 
with the heterodimer produces structural changes in the 
conformation of the αβ-tubulin molecule that stabilize 
the protofilament, inhibiting microtubule depolymeriza-
tion, also enhancing tubulin ectopic (non-centrosomal) 
nucleation. As a result of the treatment, dividing cells 
assemble aberrant spindles, often multipolar, undergoing 
cell cycle arrest typically at the G2/M transition phase, 
and finally, die by apoptosis [52, 62, 63]. However, these 
drugs have several critical limitations. Among these, (i) 
their production -they derive from natural sources and 
are difficult to synthesize-, (ii) their hydrophobic nature, 
(iii) their limited therapeutic window, (iv) their unwanted 
side effects, and (iv), the most worrying fact is that their 
Fig. 2 Similarities and differences between microtubules and CNTs
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Fig. 3 Tubulin association with MWCNTs into biosynthetic filaments. Tubulin heterodimer structure. In the dimer, α-tubulin is colored in dark red 
and β-tubulin in pink. Head-to-tail tubulin heterodimer alignment assembles protofilaments of 4 nm diameter that intermingle with the MWCNTs 
and from biosynthetic tubulin filaments
Fig. 4 Intracellular MWCNTs prompt ectopic microtubule polymerization. a Diagram of the microtubule cold-depolymerization experiment. b The 
microtubule cytoskeleton (labeled in green) is cold-sensible. Upon cell exposure to 4 °C, the microtubules depolymerize and tubulin is only visible 
at the centrosome (red arrows). Upon return into permissive conditions (37 °C), microtubules regrow from the centrosomes (top, right, arrows). If 
cells were previous exposed to MWCNTs, tubulin re-polymerizes ectopically all over the cytoplasm. The figure is partially adapted from ref. [31]
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chemical properties make them substrates of resistance 
[63, 64]. Since these drugs and carbon nanotubes simi-
larly interfere with microtubule dynamics, it is feasible 
that their combined application could produce a syner-
gistic effect to prevent resistance phenomena in cancer 
cells.
  In general terms, there are two major resistance mech-
anisms to microtubule-binding drugs, those ascribed to 
drug efflux pumps [65], and those resulting from tubu-
lin modifications impeding microtubule-associated drug 
binding [64]. In addition to these, the degradation phe-
nomena of drugs can operate at the intracellular level 
(Fig. 8). Among the former, chemotherapy can be ejected 
from the cells through the expression of one or more 
energy-dependent transporters, leading to the reduc-
tion of intracellular drug levels and consequent drug 
insensitivity to multiple antitumoral drugs [65]. And the 
later resistance mechanisms include, (i) mutations in the 
binding site of the drug to the tubulin molecule, (ii) post-
translational modifications to tubulin that interfere with 
drug binding, (iii) changes to the tubulin/microtubule-
regulatory proteins, (iv) or even changes in the tubulin 
composition of microtubules. Besides, cancer cells can 
modify signalling pathways to exit mitosis bypassing the 
`security mechanisms´ (a phenomenon called mitotic 
slippage) thus avoiding the drug-triggered apoptotic 
effect [62, 66].
In this sense, the use of CNTs as drug adjuvant and/
or carriers has the potential to completely transform 
the traditional antineoplastic treatments. CNTs, can-
not be secreted out of the cells (like drugs that are 
small molecules) and are not easily degraded, and their 
microtubule-binding properties can play a pivotal effect 
in boosting the cytotoxic properties of the microtubule-
binding drugs. CNTs associate longitudinally and inter-
mingle with the tubulin polymers. Since they do not 
specifically bind to a particular tubulin type, a structural 
pocket, or a target site in the tubulin molecule, CNTs are 
not affected by tubulin mutations or posttranslational 
modifications that significantly interfere with tubulin-
binding drugs. Consequently, CNTs are not subject to 
`standard´ resistance mechanisms. Indeed, some studies 
demonstrate that CNTs can significantly boost the anti-
tumoral effect of taxol®, boosting its cytotoxic effects, 
preventing and overcoming resistance to this drug [32, 
67, 68]. More interestingly, MWCNTs have also been 
shown to boost the effect of other antitumoral drugs such 
as 5-fluorouracil [11] or doxorubicin [69, 70] that are not 
catalogued as microtubule-poisons. These drugs can be 
administered in parallel to CNTs, or can be loaded using 
these as carriers, forming stable covalent bonds or supra-
molecular assemblies based on noncovalent interactions 
[6]. In most cases, CNTs have the carried drugs phys-
isorbed to their nanotube surfaces by π- π stacking [11, 
71].
Fig. 5 Changes in the microtubule organization in cells treated with MWCNTs. a Diagram of the microtubule disposition in control (untreated) cells, 
and cells treated with MWCNTs. Centrosomes are indicated with green-white arrows. b The disassembly of the centrosomes (red-white arrow) and 
the appearance of parallel microtubules is a consequence of MWCNT-induced microtubule stability. The figure is partially adapted from ref. [35]
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Finding ways for CNT administration in vivo
Finally, we want to briefly comment on how CNTs could 
be administered in vivo. Numerous research groups have 
shown how these nanomaterials-upon resuspension-, 
can be injected directly intravenously. Injected CNTs 
distribute throughout most of the organs-including the 
brain-, and are mainly retained in the lungs, liver, and 
spleen, being eliminated through the kidney and bile duct 
[72–75]. If CNTs are inhaled, aspirated or instilled in 
the pharynx or intratrachealy, the nanotubes have been 
reported to trigger inflammation and genotoxic effects 
in the lungs [76, 77]. But interestingly, and as expected 
by the in  vitro results, the pulmonary toxicity of well-
dispersed CNTs is more severe if the nanotubes are 
well-dispersed [73]. Alternatively, CNTs can be injected 
locally, i.e. intratumorally. This is how many of the stud-
ies that have served to investigate the antitumor effect of 
these nanomaterials have been carried out [32, 78].
Conclusions
Carbon nanotubes, and more particularly MWCNTs, can 
trigger important biomechanical effects mostly result-
ing from their similarities to microtubules that prompt 
their interaction in the cells. They intermingle with the 
protofilaments of microtubules in living cells, stabilizing 
the microtubule protofilament latices, disorganizing the 
radial microtubule cytoskeleton. As result, MWCNTs 
interfere with cell migration and division, finally lead-
ing to apoptosis in highly proliferative cells. Thus, these 
nanomaterials behave like taxanes, some of the tradi-
tional and most successful chemotherapeutics, as a new 
class of microtubule-stabilizing agents.
Since, drug resistance is inherent to the nature of can-
cer where cells create continuously adaptation strategies-, 
we believe CNTs could represent a new complementary 
therapeutic approach against cancer cell resistance used 
Fig. 6 MWCNTs produce an anti-migratory effect on cancer. a Migration trajectories of EB1 centrosome-labelled HeLa cells. Cell nuclei are labeled 
in blue, centrosomes in red and the centrosomal trajectories in green. The migration and the nuclear-centrosome axis directions are indicated in 
white and yellow, respectively. Cells treated with MWCNTs for 72 h display aberrant migration directions. As a result, their migration trajectories are 
shorter. b Calculated speeds for Hela cells and cancer cells exposed to MWCNTs. A maximum speed reduction was observed for HeLa cells. The 
figure is partially adapted from ref. [35]
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Fig. 7 MWCNTs interference with the cell cycle. a Diagram comparing mitosis in untreated versus MWCNT-treated cells. Spindle formation is 
abnormal (apolar, tripolar, or multipolar) in the presence of MWCNTs leading to mitotic blockage and apoptosis. b Phases of a normal cell cycle (top) 
compared to that in cells treated with MWCNTs (bottom)
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in combination with traditional microtubule-binding 
drugs, such as  Taxol® (paclitaxel) or Epothilones, or even 
chemicals that operate at a different antiproliferative step, 
i.e. inhibiting DNA replication—such as Doxorubicin or 
5-fluorouracil- to boot their effect. Moreover, MWCNTs 
could be used as active excipients in drug delivery sys-
tems, considering their intrinsic antitumoral properties, 
enhancing the therapeutic effect of traditional chemo-
therapy while preventing drug resistance in cancer.
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